Retrophin Inc (NASDAQ:RTRX)’s stock price rose 9.3% during mid-day trading on Wednesday . The stock traded as high as $12.02 and last traded at $13.07, approximately 18,239 shares changed hands during trading. A decline of 97% from the average daily volume of 553,725 shares. The stock had previously closed at $11.96.
RTRX has been the subject of several research analyst reports. BidaskClub lowered Retrophin from a “buy” rating to a “hold” rating in a research note on Wednesday, March 18th. Barclays downgraded Retrophin from an “overweight” rating to an “equal weight” rating and set a $19.00 price target on the stock. in a research report on Tuesday, February 25th. Zacks Investment Research downgraded Retrophin from a “buy” rating to a “hold” rating in a research report on Wednesday, January 1st. Finally, ValuEngine upgraded Retrophin from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $26.57.
The stock has a 50-day simple moving average of $14.88 and a two-hundred day simple moving average of $13.73. The company has a quick ratio of 4.43, a current ratio of 4.50 and a debt-to-equity ratio of 0.93. The firm has a market cap of $618.34 million, a PE ratio of -4.11 and a beta of 0.78.
Retrophin (NASDAQ:RTRX) last released its quarterly earnings results on Monday, February 24th. The biopharmaceutical company reported ($0.70) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.69) by ($0.01). Retrophin had a negative net margin of 83.51% and a negative return on equity of 56.87%. The firm had revenue of $46.69 million for the quarter, compared to analysts’ expectations of $46.60 million. During the same quarter in the previous year, the business earned ($0.21) EPS. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. Research analysts expect that Retrophin Inc will post -2.74 earnings per share for the current year.
In other news, insider Noah L. Rosenberg sold 1,790 shares of Retrophin stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $15.36, for a total value of $27,494.40. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP William E. Rote sold 3,250 shares of Retrophin stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $14.87, for a total value of $48,327.50. Following the completion of the transaction, the senior vice president now owns 25,646 shares in the company, valued at approximately $381,356.02. The disclosure for this sale can be found here. Insiders have sold 22,899 shares of company stock worth $348,724 in the last 90 days. Company insiders own 4.32% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in RTRX. State Street Corp increased its holdings in shares of Retrophin by 33.1% in the third quarter. State Street Corp now owns 2,152,423 shares of the biopharmaceutical company’s stock worth $24,947,000 after buying an additional 535,168 shares during the period. RA Capital Management L.P. increased its holdings in shares of Retrophin by 6.6% in the fourth quarter. RA Capital Management L.P. now owns 4,252,453 shares of the biopharmaceutical company’s stock worth $60,385,000 after buying an additional 264,893 shares during the period. Jacobs Levy Equity Management Inc. increased its holdings in shares of Retrophin by 52.7% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 624,567 shares of the biopharmaceutical company’s stock worth $8,869,000 after buying an additional 215,474 shares during the period. Schonfeld Strategic Advisors LLC purchased a new position in shares of Retrophin in the fourth quarter worth about $2,010,000. Finally, Renaissance Technologies LLC increased its holdings in shares of Retrophin by 20.0% in the fourth quarter. Renaissance Technologies LLC now owns 816,827 shares of the biopharmaceutical company’s stock worth $11,599,000 after buying an additional 135,902 shares during the period. Hedge funds and other institutional investors own 99.72% of the company’s stock.
Retrophin Company Profile (NASDAQ:RTRX)
Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.
Featured Article: Trading signals using Bollinger bands
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.